A Phase 2 interventional study of Dostarlimab and Bevacizumab in Ovarian Neoplasm, sponsored by Tesaro, Inc.. Completed at 10 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-21.
Sponsored by Tesaro, Inc. (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Ovarian Neoplasms by GlaxoSmithKline — 5 open to participants now, 7 under way, 5 of them phase 3. Ovarian Neoplasms · GlaxoSmithKline.
Among the 31 studies in Ovarian Neoplasms by GlaxoSmithKline, this one is the 19th largest by enrollment of the 30 interventional ones that give a count, is one of 4 that started in 2018, is one of 15 in phase 2, and was the 26th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →5 of the 31 studies in Ovarian Neoplasms by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Argentina, Australia, Canada and 2 more countries
Ages 18+ · Women only
GlaxoSmithKline · Sites in Australia, Canada, Japan and 1 more country
Ages 18+ · Women only
GlaxoSmithKline · Sites in Australia, Canada, Japan and 2 more countries
Ages 18+ · Women only
GlaxoSmithKline · Sites in United States, Austria, Canada and 5 more countries
Ages 18+
GlaxoSmithKline
Ages 18+ · Women only
By country, each count listing its studies:
Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 16 · Phase 3 7 · Phase 4 1
First in 1997; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 54 across 2,553 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 77 across the 30 interventional studies. Of the 22 that completed or were terminated, 16 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Tesaro, Inc., one of the names counted as GlaxoSmithKline. Under that name alone:
Tesaro, Inc. is the lead sponsor of 33 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 12 (100%) have results posted.
1 of the studies in Ovarian Neoplasms by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04641247GlaxoSmithKlineA Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study | 2026-12-28 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies in Ovarian Neoplasms by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this sub study is to evaluate the efficacy of the combination of TSR-042, bevacizumab, and niraparib in participants with advanced, relapsed, high-grade ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 2 prior lines of anticancer therapy, are PARP inhibitor naïve, and have platinum-resistant but not refractory disease.
This study is a sub study of the master protocol - OPAL (NCT03574779).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participant has a history of recent major thromboembolic event defined as follows:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Dostarlimab · Drug: Bevacizumab · Drug: Niraparib
Dostarlimab was administered.
Also known as: TSR-042
Bevacizumab was administered.
Also known as: Avastin
Niraparib was administered.
Also known as: ZEJULA
Confirmed Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Assessment
ORR was defined as percentage of participants with a confirmed investigator-assessed Best Overall Response (BOR) of confirmed complete response (CR) or partial response (PR), evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. CR is defined as the disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm).
Time frame: Up to approximately 38 Months
Progression Free Survival (PFS) Per RECIST Version 1.1 by Investigator Assessment
PFS was defined as the time from the date of the first dose of study treatment to the earliest date of assessment of disease progression or death by any cause in the absence of progression by RECIST v1.1. Disease Progression is defined using RECIST v1.1 as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: Up to approximately 38 Months
Overall Survival (OS)
OS was defined as the time from the date of the first dose of study treatment to the date of death due to any cause. Median and 95% CI are presented.
Time frame: Up to approximately 38 Months
Duration of Response (DOR) Per RECIST Version 1.1 by Investigator Assessment
DOR was defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression by RECIST version 1.1 based on Investigator's assessment or death by any cause. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm).
Time frame: Up to approximately 38 Months
Disease Control Rate (DCR) Per RECIST Version 1.1 by Investigator Assessment
DCR was defined as the percentage of participants who have achieved best overall response of CR, PR, or stable disease (SD) per RECIST version 1.1 based on Investigator's assessment. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm). Stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: Up to approximately 38 Months
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 38 Months
Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters - Chemistry, Coagulation, Hematology and Thyroid
Blood samples were collected for the analysis of clinical laboratory parameters - chemistry, coagulation, hematology and thyroid.
Time frame: Up to approximately 38 Months
Absolute Values in Urinalysis Parameter - Specific Gravity (Ratio)
Urine samples were collected at indicated time points for the assessment of specific gravity. Baseline is defined as the most recent non-missing measurement prior to or on the first administration of study drug.
Time frame: Baseline (Day 1) and end of treatment (Up to approximately 32 months)
Change From Baseline in Cancer Antigen 125 (CA-125) at End of Treatment
Blood samples were collected for the analysis of CA-125. Baseline is defined as the most recent non-missing measurement prior to or on the first administration of study drug.
Time frame: Baseline (Day 1) and end of treatment (Up to approximately 32 months)
Change From Baseline in Vital Signs (Weight) at End of Treatment
Weight was measured in ordinary indoor clothing (without shoes) and was recorded at specified study visit. Baseline is defined as the most recent non-missing measurement prior to or on the first administration of study drug.
Time frame: Baseline (Day 1) and end of treatment (Up to approximately 32 months)
Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status at Baseline and End of Treatment
Performance status assessments were based on 5-grade ECOG scale (from 0 to 4), where 0=fully active, able to carry on all pre-disease performance without restriction; 1=restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (e.g., light house work, office work); 2=ambulatory and capable of all self-care but unable to carry out any work activities, up and about more than 50% of waking hours; 3=capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4=completely disabled, cannot carry on any self-care, totally confined to bed or chair. Baseline is defined as the most recent non-missing measurement prior to or on the first administration of study drug.
Time frame: Baseline (Day 1) and end of treatment (Up to approximately 32 months)
| Milestone | Cohort A (Dostarlimab + Bevacizumab + Niraparib) |
|---|---|
| Started | 41 |
| Completed | 0 |
| Not completed | 41 |
| Withdrew: Withdrawal by subject | 6 |
| Withdrew: Death | 25 |
| Withdrew: Study site closed | 9 |
| Withdrew: Physician decision | 1 |
ORR was defined as percentage of participants with a confirmed investigator-assessed Best Overall Response (BOR) of confirmed complete response (CR) or partial response (PR), evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. CR is defined as the disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm).
| Percentage of participants | Cohort A (Dostarlimab + Bevacizumab + Niraparib) |
|---|---|
| Confirmed Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Assessment | 17.9 (10.3 to 28.3) |
PFS was defined as the time from the date of the first dose of study treatment to the earliest date of assessment of disease progression or death by any cause in the absence of progression by RECIST v1.1. Disease Progression is defined using RECIST v1.1 as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| Months | Cohort A (Dostarlimab + Bevacizumab + Niraparib) |
|---|---|
| Progression Free Survival (PFS) Per RECIST Version 1.1 by Investigator Assessment | 7.92 (4.17 to 10.87) |
OS was defined as the time from the date of the first dose of study treatment to the date of death due to any cause. Median and 95% CI are presented.
| Months | Cohort A (Dostarlimab + Bevacizumab + Niraparib) |
|---|---|
| Overall Survival (OS) | 22.05 (11.14 to 26.25) |
DOR was defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression by RECIST version 1.1 based on Investigator's assessment or death by any cause. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm).
| Months | Cohort A (Dostarlimab + Bevacizumab + Niraparib) |
|---|---|
| Duration of Response (DOR) Per RECIST Version 1.1 by Investigator Assessment | 11.76 (4.86 to 23.98) |
DCR was defined as the percentage of participants who have achieved best overall response of CR, PR, or stable disease (SD) per RECIST version 1.1 based on Investigator's assessment. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm). Stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
| Percentage of participants | Cohort A (Dostarlimab + Bevacizumab + Niraparib) |
|---|---|
| Disease Control Rate (DCR) Per RECIST Version 1.1 by Investigator Assessment | 76.9 (66.0 to 85.6) |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.
| Participants | Cohort A (Dostarlimab + Bevacizumab + Niraparib) |
|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 41 |
Blood samples were collected for the analysis of clinical laboratory parameters - chemistry, coagulation, hematology and thyroid.
| Participants | Cohort A (Dostarlimab + Bevacizumab + Niraparib) |
|---|---|
| Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters - Chemistry, Coagulation, Hematology and Thyroid | 0 |
Urine samples were collected at indicated time points for the assessment of specific gravity. Baseline is defined as the most recent non-missing measurement prior to or on the first administration of study drug.
| Ratio | Cohort A (Dostarlimab + Bevacizumab + Niraparib) |
|---|---|
| Baseline | 1.0149 ± 0.00794 |
| End of treatment | 1.0162 ± 0.00786 |
Blood samples were collected for the analysis of CA-125. Baseline is defined as the most recent non-missing measurement prior to or on the first administration of study drug.
| Units per milliliter (U/mL) | Cohort A (Dostarlimab + Bevacizumab + Niraparib) |
|---|---|
| Change From Baseline in Cancer Antigen 125 (CA-125) at End of Treatment | 246.86 ± 608.985 |
Weight was measured in ordinary indoor clothing (without shoes) and was recorded at specified study visit. Baseline is defined as the most recent non-missing measurement prior to or on the first administration of study drug.
| kilogram | Cohort A (Dostarlimab + Bevacizumab + Niraparib) |
|---|---|
| Change From Baseline in Vital Signs (Weight) at End of Treatment | -5.07 ± 5.475 |
Performance status assessments were based on 5-grade ECOG scale (from 0 to 4), where 0=fully active, able to carry on all pre-disease performance without restriction; 1=restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (e.g., light house work, office work); 2=ambulatory and capable of all self-care but unable to carry out any work activities, up and about more than 50% of waking hours; 3=capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4=completely disabled, cannot carry on any self-care, totally confined to bed or chair. Baseline is defined as the most recent non-missing measurement prior to or on the first administration of study drug.
| Participants | Cohort A (Dostarlimab + Bevacizumab + Niraparib) |
|---|---|
| Baseline — Grade 0 | 18 |
| Baseline — Grade 1 | 22 |
| Baseline — Grade 2 | 0 |
| Baseline — Grade 3 | 0 |
| Baseline — Grade 4 | 0 |
| End of Treatment — Grade 0 | 9 |
| End of Treatment — Grade 1 | 20 |
| End of Treatment — Grade 2 | 7 |
| End of Treatment — Grade 3 | 1 |
| End of Treatment — Grade 4 | 0 |
Collected over All-cause mortality, non-serious advents (Non-SAEs) and serious adverse events (SAE) were collected up to 38 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A (Dostarlimab + Bevacizumab + Niraparib) | 25/41 (61%) | 22/41 (53.7%) | 41/41 (100%) |
| Event | Cohort A (Dostarlimab + Bevacizumab + Niraparib) |
|---|---|
| Small intestinal obstructionGastrointestinal disorders | 4/41 |
| Abdominal painGastrointestinal disorders | 3/41 |
| VomitingGastrointestinal disorders | 2/41 |
| AnaemiaBlood and lymphatic system disorders | 2/41 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/41 |
| HypertensionVascular disorders | 2/41 |
| ColitisGastrointestinal disorders | 1/41 |
| GastritisGastrointestinal disorders | 1/41 |
| IleusGastrointestinal disorders | 1/41 |
| Intestinal obstructionGastrointestinal disorders | 1/41 |
| Event | Cohort A (Dostarlimab + Bevacizumab + Niraparib) |
|---|---|
| FatigueGeneral disorders | 30/41 |
| NauseaGastrointestinal disorders | 28/41 |
| VomitingGastrointestinal disorders | 23/41 |
| HypertensionVascular disorders | 20/41 |
| AnaemiaBlood and lymphatic system disorders | 19/41 |
| Platelet count decreasedInvestigations | 17/41 |
| Abdominal painGastrointestinal disorders | 16/41 |
| HeadacheNervous system disorders | 16/41 |
| ConstipationGastrointestinal disorders | 15/41 |
| Aspartate aminotransferase increasedInvestigations | 15/41 |
| Age, Continuous(years) | Cohort A (Dostarlimab + Bevacizumab + Niraparib) |
|---|---|
| Mean | 63.8 ± 10.59 |
| Sex: Female, Male(Participants) | Cohort A (Dostarlimab + Bevacizumab + Niraparib) |
|---|---|
| Female | 41 |
| Male | 0 |
| Ethnicity (NIH/OMB)(Participants) | Cohort A (Dostarlimab + Bevacizumab + Niraparib) |
|---|---|
| Hispanic or Latino | 5 |
| Not Hispanic or Latino | 36 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Cohort A (Dostarlimab + Bevacizumab + Niraparib) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 32 |
| More than one race | 0 |
| Unknown or Not Reported | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk.com
Ran from Nov 2018 to primary completion in Apr 2022, 40 months.
Results were first posted in Apr 2023, 1 year after primary completion.
Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's 40 months is close to that.
Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dostarlimab